281
ery to prostate cancer cells. Oncotarget
9(88):35813–35829
46. Daga M, Pizzimenti S, Dianzani C et al
(2019) Ailanthone inhibits cell growth and
migration of cisplatin resistant bladder cancer cells through down-regulation of Nrf2,
YAP, and c-Myc expression. Phytomedicine
56:156–164
47. Tannous M, Caldera F, Argenziano M
et al. Glutathione responsive nanosponges
for controlled ailanthone delivery. In:
Macromolecules in drug delivery, Salerno,
2017
48. O'Brien Z, Fallah Moghaddam M (2013)
Small molecule kinase inhibitors approved
by the FDA from 2000 to 2011: a systematic review of preclinical ADME
data. Expert Opin Drug Metab Toxicol
9(12):1597–1612
49. Dora CP, Trotta F, Kushwah V et al (2016)
Potential of erlotinib cyclodextrin nanosponge
complex to enhance solubility, dissolution
rate, in vitro cytotoxicity and oral bioavailability. Carbohydr Polym 137:339–349
50. Momin MM, Zaheer Z, Zainuddin R et al
(2018) Extended release delivery of erlotinib glutathione nanosponge for targeting
lung cancer. Artif Cells Nanomed Biotechnol
46(5):1064–1075
51. Vane JR, Botting RM (2003) The mechanism of action of aspirin. Thromb Res
110(5–6):255–258
52. Shende PK, Trotta F, Gaud RS et al (2012)
Influence of different techniques on formulation and comparative characterization of inclusion complexes of ASA with
b- cyclodextrin and inclusion complexes of
ASA with PMDA cross-linked b- cyclodextrin
nanosponges. J Incl Phenom Macrocycl
Chem 74(1–4):447–454
53. Packman E, Leyva R, Kellstein D (2015)
Onset of analgesia with ibuprofen sodium in
tension-type headache: a randomized trial. J
Pharm Health Care Sci 1(1):13
54. Mele A, Castiglione F, Malpezzi L et al
(2011) HR MAS NMR, powder XRD and
Raman spectroscopy study of inclusion phenomena in βCD nanosponges. J Incl Phenom
Macrocycl Chem 69(3–4):403–409
55. Ferro M, Castiglione F, Punta C et al
(2014) Anomalous diffusion of ibuprofen
in cyclodextrin nanosponge hydrogels: an
HRMAS NMR study. Beilstein J Org Chem
10:2715–2723
56. Ferro M, Castiglione F, Pastori N et al (2017)
Dynamics and interactions of ibuprofen in
cyclodextrin nanosponges by solid-state
NMR spectroscopy. Beilstein J Org Chem
13(1):182–194
57. Santos ARS, Vedana EMA, De Freitas GAG
(1998) Antinociceptive effect of meloxicam,
in neurogenic and inflammatory nociceptive
models in mice. Inflamm Res 47(7):302–307
58. Shende PK, Gaud RS, Bakal R et al (2015) 25.
Effect of inclusion complexation of meloxicam with β-cyclodextrin- and β-cyclodextrinbased nanosponges on solubility, in vitro
release and stability studies. Colloids Surf B:
Biointerfaces 136:105–110
59. Lembo D, Trotta F, Cavalli R (2018)
Cyclodextrin-based nanosponges as vehicles
for antiviral drugs: challenges and perspectives. Nanomedicine (Lond) 13(5):477–480
60. Lembo D, Donalisio M, Civra A et al (2018)
Nanomedicine formulations for the delivery
of antiviral drugs: a promising solution for
the treatment of viral infections. Expert Opin
Drug Deliv 15(1):93–114
61. Cavalli R, Donalisio M, Civra A et al
(2009) Enhanced antiviral activity of acyclovir loaded into β-cyclodextrin-poly
(4- acryloylmorpholine) conjugate nanoparticles. J Control Release 137(2):116–122
62. Lembo D, Swaminathan S, Donalisio M et al
(2013) Encapsulation of acyclovir in new carboxylated cyclodextrin-based nanosponges
improves the agent's antiviral efficacy. Int J
Pharm 443(1–2):262–272
63. Rao MR, Chaudhari J, Trotta F et al
(2018) Investigation of cyclodextrin-based
nanosponges for solubility and bioavailability enhancement of rilpivirine. AAPS
PharmSciTech 19(5):1–12
64. Rao MR, Shirsath C (2017) Enhancement of
bioavailability of non-nucleoside reverse transcriptase inhibitor using nanosponges. AAPS
PharmSciTech 18(5):1728–1738
65. Bastiancich C, Scutera S, Alotto D et al (2014)
Cyclodextrin-based nanosponges as a nanotechnology strategy for imiquimod delivery
in pathological scarring prevention and treatment. J Nanopharm Drug Del 2(4):311–324
66. Argenziano M, Haimhoffer A, Bastiancich
C et al (2019) In vitro enhanced skin permeation and retention of Imiquimod loaded
in β-cyclodextrin nanosponge hydrogel.
Pharmaceutics 11:138
67. Lee AL, Ng VW, Poon GL et al (2015)
Co-delivery of antiviral and antifungal
therapeutics for the treatment of sexually
transmitted infections using a moldable,
supramolecular hydrogel. Adv Healthc Mater
4(3):385–394
68. Sharma R, Pathak K (2011) Polymeric nanosponges as an alternative carrier for improved
retention of econazole nitrate onto the skin
through topical hydrogel formulation. Pharm
Dev Technol 16(4):367–376
69. Vavia PR, Swaminathan S, Trotta F et al
(2006) Applications of nanosponges in drug
delivery. In: Proceedings XIII International
cyclodextrin symposium, Turin
Drug-Encapsulated Cyclodextrin Nanosponges
ery to prostate cancer cells. Oncotarget
9(88):35813–35829
46. Daga M, Pizzimenti S, Dianzani C et al
(2019) Ailanthone inhibits cell growth and
migration of cisplatin resistant bladder cancer cells through down-regulation of Nrf2,
YAP, and c-Myc expression. Phytomedicine
56:156–164
47. Tannous M, Caldera F, Argenziano M
et al. Glutathione responsive nanosponges
for controlled ailanthone delivery. In:
Macromolecules in drug delivery, Salerno,
2017
48. O'Brien Z, Fallah Moghaddam M (2013)
Small molecule kinase inhibitors approved
by the FDA from 2000 to 2011: a systematic review of preclinical ADME
data. Expert Opin Drug Metab Toxicol
9(12):1597–1612
49. Dora CP, Trotta F, Kushwah V et al (2016)
Potential of erlotinib cyclodextrin nanosponge
complex to enhance solubility, dissolution
rate, in vitro cytotoxicity and oral bioavailability. Carbohydr Polym 137:339–349
50. Momin MM, Zaheer Z, Zainuddin R et al
(2018) Extended release delivery of erlotinib glutathione nanosponge for targeting
lung cancer. Artif Cells Nanomed Biotechnol
46(5):1064–1075
51. Vane JR, Botting RM (2003) The mechanism of action of aspirin. Thromb Res
110(5–6):255–258
52. Shende PK, Trotta F, Gaud RS et al (2012)
Influence of different techniques on formulation and comparative characterization of inclusion complexes of ASA with
b- cyclodextrin and inclusion complexes of
ASA with PMDA cross-linked b- cyclodextrin
nanosponges. J Incl Phenom Macrocycl
Chem 74(1–4):447–454
53. Packman E, Leyva R, Kellstein D (2015)
Onset of analgesia with ibuprofen sodium in
tension-type headache: a randomized trial. J
Pharm Health Care Sci 1(1):13
54. Mele A, Castiglione F, Malpezzi L et al
(2011) HR MAS NMR, powder XRD and
Raman spectroscopy study of inclusion phenomena in βCD nanosponges. J Incl Phenom
Macrocycl Chem 69(3–4):403–409
55. Ferro M, Castiglione F, Punta C et al
(2014) Anomalous diffusion of ibuprofen
in cyclodextrin nanosponge hydrogels: an
HRMAS NMR study. Beilstein J Org Chem
10:2715–2723
56. Ferro M, Castiglione F, Pastori N et al (2017)
Dynamics and interactions of ibuprofen in
cyclodextrin nanosponges by solid-state
NMR spectroscopy. Beilstein J Org Chem
13(1):182–194
57. Santos ARS, Vedana EMA, De Freitas GAG
(1998) Antinociceptive effect of meloxicam,
in neurogenic and inflammatory nociceptive
models in mice. Inflamm Res 47(7):302–307
58. Shende PK, Gaud RS, Bakal R et al (2015) 25.
Effect of inclusion complexation of meloxicam with β-cyclodextrin- and β-cyclodextrinbased nanosponges on solubility, in vitro
release and stability studies. Colloids Surf B:
Biointerfaces 136:105–110
59. Lembo D, Trotta F, Cavalli R (2018)
Cyclodextrin-based nanosponges as vehicles
for antiviral drugs: challenges and perspectives. Nanomedicine (Lond) 13(5):477–480
60. Lembo D, Donalisio M, Civra A et al (2018)
Nanomedicine formulations for the delivery
of antiviral drugs: a promising solution for
the treatment of viral infections. Expert Opin
Drug Deliv 15(1):93–114
61. Cavalli R, Donalisio M, Civra A et al
(2009) Enhanced antiviral activity of acyclovir loaded into β-cyclodextrin-poly
(4- acryloylmorpholine) conjugate nanoparticles. J Control Release 137(2):116–122
62. Lembo D, Swaminathan S, Donalisio M et al
(2013) Encapsulation of acyclovir in new carboxylated cyclodextrin-based nanosponges
improves the agent's antiviral efficacy. Int J
Pharm 443(1–2):262–272
63. Rao MR, Chaudhari J, Trotta F et al
(2018) Investigation of cyclodextrin-based
nanosponges for solubility and bioavailability enhancement of rilpivirine. AAPS
PharmSciTech 19(5):1–12
64. Rao MR, Shirsath C (2017) Enhancement of
bioavailability of non-nucleoside reverse transcriptase inhibitor using nanosponges. AAPS
PharmSciTech 18(5):1728–1738
65. Bastiancich C, Scutera S, Alotto D et al (2014)
Cyclodextrin-based nanosponges as a nanotechnology strategy for imiquimod delivery
in pathological scarring prevention and treatment. J Nanopharm Drug Del 2(4):311–324
66. Argenziano M, Haimhoffer A, Bastiancich
C et al (2019) In vitro enhanced skin permeation and retention of Imiquimod loaded
in β-cyclodextrin nanosponge hydrogel.
Pharmaceutics 11:138
67. Lee AL, Ng VW, Poon GL et al (2015)
Co-delivery of antiviral and antifungal
therapeutics for the treatment of sexually
transmitted infections using a moldable,
supramolecular hydrogel. Adv Healthc Mater
4(3):385–394
68. Sharma R, Pathak K (2011) Polymeric nanosponges as an alternative carrier for improved
retention of econazole nitrate onto the skin
through topical hydrogel formulation. Pharm
Dev Technol 16(4):367–376
69. Vavia PR, Swaminathan S, Trotta F et al
(2006) Applications of nanosponges in drug
delivery. In: Proceedings XIII International
cyclodextrin symposium, Turin
Drug-Encapsulated Cyclodextrin Nanosponges